Asian-News.net is your go-to online destination for comprehensive coverage of major news across Asia. From politics and business to culture and technology, we bring you the latest updates, deep analyses, and critical insights from every corner of the continent. Featuring exclusive interviews, high-quality photos, and engaging videos, we keep you informed on the breaking news and significant events shaping Asia. Stay connected with us to get a 24/7 update on the most important stories and trends. Our daily updates ensure that you never miss a beat on the happenings in Asia's diverse nations. Whether it's a political shift in China, economic development in India, technological advancements in Japan, or cultural events in Southeast Asia, Asian-News.net has it covered. Dive into the world of Asian news with us and stay ahead in understanding this dynamic and vibrant region.
Novo Nordisk shares climbed 8% on Thursday, hitting a fresh record high after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug.
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest economy.
LONDON — Shares of Denmark's Zealand Pharma popped on Friday, notching a record high after an early-stage study of its weight loss drug challenger produced positive results.
LONDON — The rapid rise of weight loss drugs like Wegovy is generating a host of new product lines as companies hope to land on the right side of the health care disruptor.
Alphabet's outgoing finance chief, Ruth Porat, spent the past year and a half trying to help her internet company navigate the generative artificial intelligence boom. The person who was just named her successor was knee-deep in a very different phenomenon: anti-obesity drugs.
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.
Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity.
Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.
A highly popular group of weight loss and diabetes drugs is decreasing some consumers' appetites — and also how much they spend on food.